/MLTX
MLTX Stock - MoonLake Immunotherapeutics
Healthcare|BiotechnologyNASDAQ
$13.39+0.98%
+$0.13 (+0.98%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.72
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+46.1%upside
Target: $19.56
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MLTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$13.26 – $13.52
TARGET (TP)$19.56
STOP LOSS$12.32
RISK/REWARD1:5.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.21
52W High$62.75
52W Low$5.95
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | $-4,971 | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-143,091,082 | $-54,123,096 | $-65,061,417 | $-53,577,012 | $-105,755 |
| Net Income | $-118,935,517 | $-36,007,260 | $-49,973,249 | $-53,643,615 | $-90,838 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.89 | $-0.73 | $-2.20 | $-1.45 | $-0.01 |
Company Overview
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
18
62%
Hold / Neutral
10
34%
Sell / Underperform
1
3%
Analyst Consensus🟡 Mixed
18 Bullish11 Neutral/Bearish
Price Targets
$42
Average Target
↑ 215.9% Upside
Now
$2
Low
$42
Average
$104
High
Based on 27 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 3rd 2025 | H.C. Wainwright | Upgrade | Buy | $30 |
| October 2nd 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| October 1st 2025 | Goldman | Downgrade | Neutral | $7 |
| September 30th 2025 | Wolfe Research | Downgrade | Underperform | $2 |
| September 30th 2025 | Citigroup | Downgrade | Neutral | $5 |
| September 29th 2025 | Jefferies | Downgrade | Hold | $8 |
| September 29th 2025 | BTIG Research | Downgrade | Neutral | - |
| September 29th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $10 |
| September 29th 2025 | Stifel | Downgrade | Hold | $13 |
| July 28th 2025 | Rothschild & Co Redburn | Initiation | Neutral | $65 |
| May 19th 2025 | Wolfe Research | Upgrade | Outperform | $61 |
| March 18th 2025 | RBC Capital Mkts | Initiation | Outperform | $67 |
| January 17th 2025 | Goldman | Upgrade | Buy | $82← $62 |
| November 5th 2024 | Wedbush | Resumed | Outperform | $73← $92 |
| August 26th 2024 | Wolfe Research | Downgrade | Peer Perform | - |
Earnings History & Surprises
MLTXBeat Rate
57%
Last 14 quarters
Avg Surprise
+0.7%
EPS vs Estimate
Beats / Misses
8/6
Last 12 quarters
Latest EPS
$-1.10
Q4 2025
EPS Surprise History
Q1 24
+42.9%
$-0.12vs$-0.21
Q2 24
-4.8%
$-0.22vs$-0.21
Q3 24
-39.3%
$-0.39vs$-0.28
Q4 24
-27.3%
$-0.56vs$-0.44
Q1 25
-35.8%
$-0.72vs$-0.53
Q2 25
+17.1%
$-0.63vs$-0.76
Q3 25
-19.2%
$-0.87vs$-0.73
Q4 25
-23.6%
$-1.10vs$-0.89
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.97 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.89 | $-1.10 | -23.6% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.73 | $-0.87 | -19.2% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.76 | $-0.63 | +17.1% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $-0.53 | $-0.72 | -35.8% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.44 | $-0.56 | -27.3% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.28 | $-0.39 | -39.3% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.21 | $-0.22 | -4.8% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $-0.21 | $-0.12 | +42.9% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.22 | $-0.18 | +18.2% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.25 | $-0.23 | +8.0% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-0.28 | $-0.23 | +17.9% | ✓ BEAT |
Q1 2023 | Mar 20, 2023 | $-0.32 | $-0.31 | +3.1% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.32 | $-0.27 | +15.6% | ✓ BEAT |
Q3 2022 | Aug 12, 2022 | $-0.54 | $-0.34 | +37.0% | ✓ BEAT |
Q2 2022 | May 16, 2022 | — | $-0.43 | — | — |
Q1 2022 | Feb 17, 2022 | — | $-0.15 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-0.17 | — | — |
Q3 2021 | Aug 16, 2021 | — | $-0.89 | — | — |
Latest News
HC Wainwright & Co. Maintains Buy on MoonLake, Lowers Price Target to $26
📈 PositiveBenzinga•Nov 21, 2025, 11:23 AM
MoonLake Reports Clinical Data From Sonelokimab Studies, Nanobody Drug Shows Results In Multiple Trials For Rare Skin Diseases, Eyes FDA Filing In 2026
📈 PositiveBenzinga•Nov 5, 2025, 12:21 PM
Moonlake Immunotherapeutics Priced An Underwritten Offering Of 7.14M Shares At $10.50/Share, With Gross Proceeds Of Approximately $75M
➖ NeutralBenzinga•Nov 5, 2025, 12:20 PM
MoonLake Q3 EPS $(1.10) Misses $(0.88) Estimate
📉 NegativeBenzinga•Nov 5, 2025, 12:13 PM
HC Wainwright & Co. Upgrades MoonLake to Buy, Announces $30 Price Target
📈 PositiveBenzinga•Nov 3, 2025, 11:59 AM
Citigroup Downgrades MoonLake to Sell, Maintains Price Target to $5
📉 NegativeBenzinga•Oct 29, 2025, 07:54 PM•Also:
HC Wainwright & Co. Downgrades MoonLake to Neutral
📉 NegativeBenzinga•Oct 2, 2025, 10:43 AM
MoonLake rebounds despite downgrades prompted by trial setback
➖ NeutralSeeking Alpha•Sep 30, 2025, 05:34 PM
Guggenheim Maintains Buy on MoonLake, Lowers Price Target to $20
➖ NeutralBenzinga•Sep 30, 2025, 02:24 PM
Wedbush Maintains Outperform on MoonLake, Lowers Price Target to $18
📈 PositiveBenzinga•Sep 30, 2025, 12:51 PM
Citigroup Downgrades MoonLake to Neutral, Lowers Price Target to $5
📉 NegativeBenzinga•Sep 30, 2025, 11:48 AM•Also:
Needham Maintains Buy on MoonLake, Lowers Price Target to $20
➖ NeutralBenzinga•Sep 30, 2025, 10:22 AM
RBC Capital Downgrades MoonLake to Sector Perform, Lowers Price Target to $10
📉 NegativeBenzinga•Sep 29, 2025, 01:43 PM
MoonLake plunges after mixed results from skin disease trial
📉 NegativeSeeking Alpha•Sep 29, 2025, 01:03 PM
MoonLake Immunotherapeutics shares are trading lower after the company's hidradenitis suppurativa trial failed to achieve statistical significance due to better-than-expected placebo response.
📉 NegativeBenzinga•Sep 29, 2025, 11:18 AM
MoonLake Immunotherapeutics Reported Sunday On Their Hidradenitis Suppurativa Program, In VELA-2, Intercurrent Events In The Higher-than-expected Placebo Arm Precluded The Study From Achieving Statistical Significance In The Week 16 Primary Endpoint Using Composite Strategy
📉 NegativeBenzinga•Sep 29, 2025, 10:48 AM
BTIG Downgrades MoonLake to Neutral, Maintains Price Target to $85
➖ NeutralBenzinga•Sep 29, 2025, 10:25 AM
Reported Sunday, MoonLake Phase 3 VELA Trials Show Sonelokimab Achieves Statistically Significant HiSCR75 Responses In Moderate To Severe Hidradenitis Suppurativa
📈 PositiveBenzinga•Sep 29, 2025, 06:35 AM
Merck made $3B+ offer for MoonLake earlier this year - report
➖ NeutralSeeking Alpha•Jun 2, 2025, 09:53 PM•Also:
Frequently Asked Questions about MLTX
What is MLTX's current stock price?
MoonLake Immunotherapeutics (MLTX) is currently trading at $13.39 per share. The stock has moved +0.98% today.
What is the analyst price target for MLTX?
The average analyst price target for MLTX is $19.56, based on 1 analyst.
What sector is MoonLake Immunotherapeutics in?
MoonLake Immunotherapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MLTX's market cap?
MoonLake Immunotherapeutics has a market capitalization of $0.85 billion, making it a small-cap company.
Does MLTX pay dividends?
No, MoonLake Immunotherapeutics does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABSI
Absci Corporation
$3.38
Mkt Cap: $0.5B
AVBP
ArriVent BioPharma, Inc. Common Stock
$22.01
Mkt Cap: $0.9B
CTMX
CytomX Therapeutics, Inc.
$4.00
Mkt Cap: $0.7B
ERAS
Erasca, Inc.
$3.45
Mkt Cap: $1.0B
MBX
MBX Biosciences, Inc. Common Stock
$30.42
Mkt Cap: $1.0B
MGTX
MeiraGTx Holdings plc
$8.03
Mkt Cap: $0.6B
OLMA
Olema Pharmaceuticals, Inc.
$27.93
Mkt Cap: $1.9B
RGNX
REGENXBIO Inc.
$14.59
Mkt Cap: $0.7B
VSTM
Verastem, Inc.
$7.76
Mkt Cap: $0.5B
VTYX
Ventyx Biosciences, Inc.
$8.74
Mkt Cap: $0.6B
Explore stocks similar to MLTX for comparison